Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Gallagher L, Xiao J, Hsueh J, Shah S, Danner M, Zwart A, Ayoob M, Yung T, Simpson T, Fallick M, Kumar D, Leger P, Dawson NA, Suy S, Collins SP. Gallagher L, et al. Among authors: dawson na. Front Oncol. 2023 Oct 17;13:1289249. doi: 10.3389/fonc.2023.1289249. eCollection 2023. Front Oncol. 2023. PMID: 37916156 Free PMC article.
Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.
Carrasquilla M, Sholklapper T, Pepin AN, Hodgins N, Lei S, Rashid A, Danner M, Zwart A, Bolanos G, Ayoob M, Yung T, Aghdam N, Collins B, Suy S, Kumar D, Hankins R, Kowalczyk K, Dawson N, Collins S. Carrasquilla M, et al. Front Oncol. 2023 Nov 23;13:1240939. doi: 10.3389/fonc.2023.1240939. eCollection 2023. Front Oncol. 2023. PMID: 38074646 Free PMC article.
Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
Shah S, Pepin A, Jatar S, Hsueh J, Gallagher L, Danner MT, Zwart A, Ayoob M, Yung TM, Kumar D, Aghdam N, Leger PD, Dawson NA, Simeng S, Collins SP. Shah S, et al. Among authors: dawson na. Cureus. 2024 Mar 7;16(3):e55729. doi: 10.7759/cureus.55729. eCollection 2024 Mar. Cureus. 2024. PMID: 38586683 Free PMC article.
Impact of neoadjuvant relugolix on patient-reported sexual function and bother.
Hsueh JY, Gallagher L, Koh MJ, Eden S, Shah S, Wells M, Danner M, Zwart A, Ayoob M, Kumar D, Leger P, Dawson NA, Suy S, Rubin R, Collins SP. Hsueh JY, et al. Among authors: dawson na. Front Oncol. 2024 Apr 11;14:1377103. doi: 10.3389/fonc.2024.1377103. eCollection 2024. Front Oncol. 2024. PMID: 38665954 Free PMC article.
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Kemeny MM, Zhao F, Forastiere AA, Catalano P, Hamilton SR, Miedema BW, Dawson NA, Weiner LM, Smith BD, Mason BA, Graziano SL, Gilman PB, Venook AP, Pinto HA, Whitehead RP, O'Dwyer PJ, Benson AB. Kemeny MM, et al. Among authors: dawson na. Ann Surg Oncol. 2023 Feb;30(2):1099-1109. doi: 10.1245/s10434-022-12705-8. Epub 2022 Oct 28. Ann Surg Oncol. 2023. PMID: 36305992 Free PMC article. Clinical Trial.
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR. Barata P, et al. Among authors: dawson na. J Clin Invest. 2024 Apr 23:e178915. doi: 10.1172/JCI178915. Online ahead of print. J Clin Invest. 2024. PMID: 38652565 Free article.
Suppression of Human Dendritic Cells by Regulatory T Cells.
Huang Q, Lam AJ, Boardman DA, Dawson NAJ, Levings MK. Huang Q, et al. Among authors: dawson naj. Bio Protoc. 2021 Nov 5;11(21):e4217. doi: 10.21769/BioProtoc.4217. eCollection 2021 Nov 5. Bio Protoc. 2021. PMID: 34859131 Free PMC article.
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
Sarker D, Dawson NA, Aparicio AM, Dorff TB, Pantuck AJ, Vaishampayan UN, Henson L, Vasist L, Roy-Ghanta S, Gorczyca M, York W, Ganji G, Tolson J, de Bono JS. Sarker D, et al. Among authors: dawson na. Clin Cancer Res. 2021 Oct 1;27(19):5248-5257. doi: 10.1158/1078-0432.CCR-21-1115. Clin Cancer Res. 2021. PMID: 34281912 Clinical Trial.
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP, Vaishampayan UN, Patel KR, Higano CS, Albany C, Dawson NA, Mehlhaff BA, Quinn DI, Nordquist LT, Wagner VJ, Siegel J, Trandafir L, Sartor O. Petrylak DP, et al. Among authors: dawson na. ESMO Open. 2021 Apr;6(2):100082. doi: 10.1016/j.esmoop.2021.100082. Epub 2021 Mar 19. ESMO Open. 2021. PMID: 33744812 Free PMC article. Clinical Trial.
92 results